miR126功能的多效性与先天性免疫

doi:10.3724/SP.J.1005.2014.0631

遗传 ›› 2014, Vol. 36 ›› Issue (7): 631-636.doi: 10.3724/SP.J.1005.2014.0631

miR126功能的多效性与先天性免疫

白玉, 陆雯芸, 韩凝, 边红武, 朱睦元

浙江大学生命科学学院遗传所, 杭州 310058

收稿日期:2014-02-26 出版日期:2014-07-20 发布日期:2014-06-23
通讯作者: 边红武, 博士, 副教授, 研究方向：遗传学。E-mail: hwbian@zju.edu.cn
作者简介:白玉, 硕士研究生, 专业方向：遗传学。E-mail: 21107046@ziu.edu.cn
基金资助:
国家自然科学基金项目(编号：31171615, 31171543)资助

Functions of miR126 and innate immune response

Yu Bai, Wenyun Lu, Ning Han, Hongwu Bian, Muyuan Zhu

Institution of Genetics, College of Life Sciences, Zhejiang University, Hangzhou 310058, China

Received:2014-02-26 Online:2014-07-20 Published:2014-06-23

摘要/Abstract

摘要： MicroRNAs (miRNAs)是一种重要的转录后水平进行调控的非编码小分子RNA。目前已发现许多miRNAs参与细胞增殖、分化、发育及凋亡等复杂的生物进程, 其中miR126是一种来源于Egfl7第7个内含子的保守型内含子miRNA, 主要在哺乳动物的内皮细胞(Endothelial cells, ECs)及浆细胞样树突状细胞(Plasmacytoid dendritic cells, pDCs)内表达, 参与血管的新生及癌细胞的增殖与迁移。最新的研究表明, miR126是迄今唯一参与先天性免疫平稳期病毒应答反应的miRNA, 预示着miR126有可能成为治疗癌症及免疫缺陷病的靶标分子。文章综述了miR126在血管新生和癌症中的功能, 并着重介绍了miR126与先天性免疫的关系。

关键词: miR126, 血管新生, 癌症, 先天性免疫

Abstract: MicroRNAs (miRNAs) are endogenous non-coding small RNAs that negatively regulate gene expression at the post-transcriptional level by base pairing with target mRNAs. Many miRNAs have been proven to regulate a broad range of processes, including proliferation, differentiation, development and apoptosis. miR126 is encoded by intron 7 of the EGF- like domain 7 (Egfl7) gene and highly expressed in human endothelial cells (ECs) and plasmacytoid dendritic cells (pDCs). Based on the current knowledge, miR126 is involved in angiogenesis and cancer. Also miR126 is the first miRNA which has been reported to involve in preconditioning the responsiveness of the host to pathogen infection in the steady state. This implicated that miR126 may be the potential therapeutic target for cancer and autoimmune diseases. In this review, we summarize the functions of miR126 in angiogenesis and cancer, and emphasize its relationship with innate immune response.

Key words: miR126, angiogenesis, cancer, innate immune

白玉, 陆雯芸, 韩凝, 边红武, 朱睦元. miR126功能的多效性与先天性免疫[J]. 遗传, 2014, 36(7): 631-636.

Yu Bai, Wenyun Lu, Ning Han, Hongwu Bian, Muyuan Zhu. Functions of miR126 and innate immune response[J]. HEREDITAS(Beijing), 2014, 36(7): 631-636.

参考文献

[1] RC, Feinbaum RL, Ambros V. The C . elegans heterochronic gene lin-4 encodes small RNAs with antisense complementarity to lin-14. Cell , 1993, 75(5): 843-854.
[2] B, Arif MA, Seumel GI, Ossowski S, Weigel D, Reski R, Frank W. Transcriptional control of gene expression by microRNAs. Cell , 2010, 140(1): 111-122.
[3] KA, Wentzel EA, Zeller KI, Dang CV, Mendell JT. c-Myc-regulated microRNAs modulate E2F1 expression. Nature , 2005, 435(7043): 839-843.
[4] EV, Zhang J, Carrasco MA, Maniatis T. The MicroRNA miR-124 promotes neuronal differentiation by triggering brain-specific alternative pre-mRNA splicing. Mol Cell , 2007, 27(3): 435-448.
[5] A, Calin GA, Fabbri M, Iorio MV, Ferracin M, Shimizu M, Wojcik SE, Aqeilan RI, Zupo S, Dono M, Rassenti L, Alder H, Volinia S, Liu CG, Kipps TJ, Negrini M, Croce CM. miR-15 and miR-16 induce apoptosis by targeting BCL2. Proc Natl Acad Sci USA , 2005, 102(39): 13944-13949.
[6] GA, Croce CM. MicroRNA signatures in human cancers. Nat Rev Cancer , 2006, 6(11): 857-866.
[7] D, Boldin MP, O'Connell RM, Rao DS, Taganov KD. MicroRNAs: new regulators of immune cell development and function. Nat Immunol , 2008, 9(8): 839-845.
[8] M, Rauhut R, Yalcin A, Meyer J, Lendeckel W, Tuschl T. Identification of Tissue-Specific MicroRNAs from mouse. Curr Biol , 2002, 12(9): 735-739.
[9] S, Aurora AB, Johnson BA, Qi X, McAnally J, Hill JA, Richardson JA, Bassel-Duby R, Olson EN. The endothelial-specific microRNA miR-126 governs vascular integrity and angiogenesis. Dev C ell , 2008, 15(2): 261-271.
[10] JE, Santoro MM, Morton SU, Yu S, Yeh RF, Wythe JD, Ivey KN, Bruneau BG, Stainier DY, Srivastava D. miR-126 regulates angiogenic signaling and vascular integrity. Dev C ell , 2008, 15(2): 272-284.
[11] L, Leahy A, Chitnis S, Koschnick S, Fitch MJ, Fallon JT, Loskutoff D, Taubman MB, Stuhlmann H. EGFL7 is a chemoattractant for endothelial cells and is up-regulated in angiogenesis and arterial injury. Am J P a thol , 2005, 167(1): 275-284.
[12] P. Angiogenesis in health and disease. Nat M ed , 2003, 9(6): 653-660.
[13] C, Sah JF, Beard L, Willson JK, Markowitz SD, Guda K. The noncoding RNA, miR-126, suppresses the growth of neoplastic cells by targeting phosphatidylinositol 3-kinase signaling and is frequently lost in colon cancers. Genes Chromosomes Cancer , 2008, 47(11): 939-946.
[14] Y, Negishi Y, Nakamura A, Ukai S, Ooaku K, Oda Y, Sugimoto K, Moriyasu F, Takagi N, Suzuki R, Maruyama K, Aramaki Y. Systemic delivery of miR-126 by miRNA-loaded Bubble liposomes for the treatment of hindlimb ischemia. Sci Rep , 2014, 4: 3883.
[15] 杨建香, 李真, 刘红云, 刘建新. 乳腺发育及泌乳相关miRNA研究进展. 遗传, 2013, 35(6): 695-702.
[16] SF, Alarcon C, Oskarsson T, Padua D, Wang Q, Bos PD, Gerald WL, Massagué J. Endogenous human microRNAs that suppress breast cancer metastasis. Nature , 2008, 451(7175): 147-152.
[17] N, Caplen N, Bowman E, Seike M, Kumamoto K, Yi M, Stephens RM, Okamoto A, Yokota J, Tanaka T, Calin GA, Liu CG, Croce CM, Harris CC. Unique microRNA molecular profiles in lung cancer diagnosis and prognosis. Cancer Cell , 2006, 9(3): 189-198.
[18] R, Chen X, Yu Y, Su L, Yu B, Li J, Cai Q, Yan M, Liu B, Zhu Z. miR-126 functions as a tumour suppressor in human gastric cancer. Cancer Lett , 2010, 298(1): 50-63.
[19] Y, Friedman JM, Chihara Y, Egger G, Chuang JC, Liang G. Epigenetic therapy upregulates the tumor suppressor microRNA-126 and its host gene EGFL7 in human cancer cells. Biochem Biophys Res Commun , 2009, 379(3): 726-731.
[20] X, Tang S, Le SY, Lu R, Rader JS, Meyers C, Zheng ZM. Aberrant expression of oncogenic and tumor- suppressive microRNAs in cervical cancer is required for cancer cell growth. PloS O NE , 2008, 3(7): e2557.
[21] B, Peng XC, Zheng XL, Wang J, Qin YW. MiR-126 restoration down-regulate VEGF and inhibit the growth of lung cancer cell lines in vitro and in vivo . Lung C ancer , 2009, 66(2): 169-175.
[22] RB, Kalodimos C, Inagaki F, Tanaka S. Crk and CrkL adaptor proteins: networks for physiological and pathological signaling. Cell Commun Signal , 2009, 7: 13.
[23] SA, Colonna M. Viral sensors: diversity in pathogen recognition. Immunol Rev , 2009, 227(1): 87-94.
[24] CA Jr, Medzhitov R. Innate immune recognition. Annu Rev Immunol , 2002, 20: 197-216.
[25] M, Trinchieri G, Liu YJ. Plasmacytoid dendritic cells in immunity. Nat Immunol , 2004, 5(12): 1219-1226.
[26] A, Rifkin IR. Immunologically active autoantigens: the role of toll-like receptors in the development of chronic inflammatory disease. Annu Rev Immunol , 2007, 25: 419-441.
[27] LA, Sheedy FJ, McCoy CE. MicroRNAs: the fine-tuners of Toll-like receptor signalling. Nat Rev Immunol , 2011, 11(3): 163-175.
[28] RM, Taganov KD, Boldin MP, Cheng G, Baltimore D. MicroRNA-155 is induced during the macrophage inflammatory response. Proc Natl Acad Sci USA , 2007, 104(5): 1604-1609.
[29] KD, Boldin MP, Chang KJ, Baltimore D. NF-kappaB-dependent induction of microRNA miR-146, an inhibitor targeted to signaling proteins of innate immune responses. Proc Natl Acad Sci USA , 2006, 103(33): 12481-12486.
[30] J, Ruzo A, Tung N, Salmon H, Leboeuf M, Hashimoto D, Becker C, Garrett-Sinha LA, Baccarini A, Merad M, Brown BD. The miR-126-VEGFR2 axis controls the innate response to pathogen-associated nucleic acids. Nat Immunol , 2014, 15(1): 54-62.
[31] P, Jain RK. Molecular mechanisms and clinical applications of angiogenesis. Nature , 2011, 473(7347): 298-307.
[32] B, Peng XC, Zheng XL, Wang J, Qin YW. MiR-126 restoration down-regulate VEGF and inhibit the growth of lung cancer cell lines in vitro and in vivo . Lung C ancer , 2009, 66(2): 169-175.
[33] WF, Hu YL, Uttarwar L, Passegue E, Largman C. MicroRNA-126 regulates HOXA9 by binding to the homeobox. Mol Cell Biol , 2008, 28(14): 4609-4619.
[34] J, Du YY, Lin YF, Chen YT, Yang L, Wang HJ, Ma D. The cell growth suppressor, mir-126, targets IRS-1. Biochem Biophys Res Commun , 2008, 377(1): 136-140.
[35] TA, Yamakuchi M, Ferlito M, Mendell JT, Lowenstein CJ. MicroRNA-126 regulates endothelial expression of vascular cell adhesion molecule 1. Proc Natl Acad Sci USA , 2008, 105(5): 1516-1521.
[36] J, Ruzo A, Tung N, Salmon H, Leboeuf M, Hashimoto D, Becker C, Garrett-Sinha LA, Baccarini A, Merad M, Brown BD. The miR-126-VEGFR2 axis controls the innate response to pathogen-associated nucleic acids. Nat I mmunol , 2014, 15(1): 54-62.
[37] DW, Cachianes G, Kuang WJ, Goeddel DV, Ferrara N. Vascular endothelial growth factor is a secreted angiogenic mitogen. Science , 1989, 246(4935): 1306- 1309.
[38] N. Vascular Endothelial Growth Factor: Basic Science and Clinical Progress. Endoc Rev , 2004, 25(4): 581-611.
[39] M, Yamaguchi S, Yamane A, Ikeda T, Tojo A, Matsushime H, Sato M. Nucleotide sequence and expression of a novel human receptor-type tyrosine kinase gene (flt) closely related to the fms family. Oncogene , 1990, 5(4): 519-524.
[40] BI, Dougher-Vermazen M, Carrion ME, Dimitrov D, Armellino DC, Gospodarowicz D, Böhlen P. Identification of the KDR tyrosine kinase as a receptor for vascular endothelial cell growth factor. Biochem Biophys Res Commun , 1992, 187(3): 1579-1586.
[41] F, Rossant J, Yamaguchi TP, Gertsenstein M, Wu XF, Breitman ML, Schuh AC. Failure of blood-island formation and vasculogenesis in Flk-1-deficient mice. Nature , 1995, 376(6535): 62-66.
[42] HF, Brown LF, Detmar M, Dvorak AM. Vascular permeability factor/vascular endothelial growth factor, microvascular hyperpermeability, and angiogenesis. Am J Pathol , 1995, 146(5): 1029-1039.
[43] F, Rak JW, Croix BS, Lieubeau B, Kaya M, Roncari L, Shirasawa S, Sasazuki T, Kerbel RS. Impact of oncogenes in tumor angiogenesis: mutant K-ras up-regulation of vascular endothelial growth factor/ vascular permeability factor is necessary, but not sufficient for tumorigenicity of human colorectal carcinoma cells. Proc Natl Acad Sci USA , 1998, 95(7): 3609-3614.
[44] KJ, Li B, Winer J, Armanini M, Gillett N, Phillips HS, Ferrara N. Inhibition of vascular endothelial growth factor-induced angiogenesis suppresses tumour growth in vivo. Nature , 1993, 362(6423): 841-844.
[45] N, Mass RD, Campa C, Kim R. Targeting VEGF-A to treat cancer and age-related macular degeneration. Annu Rev Med , 2007, 58: 491-504.
[46] D, Gielen P, Kroesen M, Wesseling P, Adema GJ. The immunosuppressive tumour network: myeloid-derived suppressor cells, regulatory T cells and natural killer T cells. Immunology , 2013, 138(2): 105-115.
[47] G, Moi D, Ranghetti A, Ozkal-Baydin P, Squadrito ML, Kajaste-Rudnitski A, Bondanza A, Gentner B, De Palma M, Mazzieri R, Naldini L. Genetic engineering of hematopoiesis for targeted IFN-α delivery inhibits breast cancer progression. Sci Transl Med , 2014, 6(217): 217ra3.

编辑推荐

Metrics

www.chinagene.cn
备案号：京ICP备09063187号-4
总访问:,今日访问:,当前在线:

miR126功能的多效性与先天性免疫

Functions of miR126 and innate immune response

PDF (PC)

可视化

被引次数

摘要/Abstract

引用本文

使用本文

参考文献

相关文章 13

编辑推荐

Metrics

[1]	张競文,续倩,李国亮. 癌症发生发展中的表观遗传学研究[J]. 遗传, 2019, 41(7): 567-581.
[2]	黄羽,胡斯奇,郭斐. 应激颗粒与病毒的相互制约[J]. 遗传, 2019, 41(6): 494-508.
[3]	吴志强, 米泽云. 超级增强子在肿瘤研究中的进展[J]. 遗传, 2019, 41(1): 41-51.
[4]	胡立桥,周兆才,田伟. Hippo信号通路结构生物学研究进展[J]. 遗传, 2017, 39(7): 659-674.
[5]	许崇凤,段子渊. 中华民族永生细胞库在生命科学研究中的支撑作用[J]. 遗传, 2017, 39(1): 75-86.
[6]	王大勇, 马宁, 惠洋, 高旭. CRISPR/Cas9基因组编辑技术在癌症研究中的应用[J]. 遗传, 2016, 38(1): 1-8.
[7]	周学, 杜宜兰, 金萍, 马飞. 癌症相关microRNA与靶基因的生物信息学分析[J]. 遗传, 2015, 37(9): 855-864.
[8]	汤静思, 杨明耀, 李英. 假基因的功能及其在癌症疾病中的重要作用[J]. 遗传, 2015, 37(1): 8-16.
[9]	张凡，林爱华，林美华，丁元林，饶绍奇. 基于双聚类挖掘癌症共享的基因功能模块[J]. 遗传, 2013, 35(3): 333-342.
[10]	李大虎，张令强，贺福初. 突变体p53研究进展[J]. 遗传, 2008, 30(6): 697-703.
[11]	李小波，陈俭，吕炳建，来茂德. 应用CGH数据和树模型探索癌症的发病机理[J]. 遗传, 2008, 30(4): 407-412.
[12]	田筱青，孙丹凤，张燕捷，房静远. 芯片技术与肿瘤中DNA甲基化研究[J]. 遗传, 2008, 30(3): 295-303.
[13]	薛昱，储明星，周忠孝. 抑制素基因的研究进展[J]. 遗传, 2004, 26(5): 749-755.